Saturday, January 05, 2019 3:09:02 PM
There is considerably less short interest
than @ $7. My guess is a LOT OF ROOM to cover even with the vig.
They have been the prime sellers of calls for a long time
for even MORE room.
Dec 2015
July-August of 2016
March-July 2017 around $6
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
12/14/2018 5,542,513 186,519 29.715541
11/30/2018 5,542,897 150,113 36.924830
11/15/2018 5,744,717 160,815 35.722520
10/31/2018 5,783,150 426,886 13.547294
10/15/2018 5,553,619 220,507 25.185681
9/28/2018 5,765,630 363,517 15.860689
9/14/2018 5,689,444 180,832 31.462595
8/31/2018 5,740,454 183,845 31.224423
8/15/2018 5,814,264 287,331 20.235422
7/31/2018 5,619,190 323,299 17.380784
7/13/2018 5,512,714 1,629,466 3.383141
6/29/2018 4,987,450 1,045,374 4.770972
6/29/2018 4,987,450 1,045,374 4.770972
6/15/2018 6,160,104 1,074,516 5.732910
5/31/2018 6,081,254 277,243 21.934743
5/15/2018 5,979,269 251,146 23.807940
4/30/2018 5,876,481 325,520 18.052596
4/13/2018 5,287,123 272,186 19.424669
3/29/2018 5,019,020 281,431 17.833927
3/15/2018 4,609,105 317,430 14.520067
2/28/2018 4,388,774 211,082 20.791797
2/15/2018 4,555,968 380,550 11.972061
1/31/2018 4,404,075 356,538 12.352330
1/12/2018 4,409,183 228,264 19.316156
12/29/2017 4,276,431 377,630 11.324394
12/15/2017 4,304,432 370,493 11.618120
11/30/2017 3,947,232 238,331 16.561975
11/15/2017 4,130,255 336,051 12.290560
10/31/2017 3,968,208 393,658 10.080344
10/13/2017 4,124,416 322,079 12.805604
9/29/2017 4,190,896 328,327 12.764396
9/15/2017 5,242,635 317,674 16.503192
8/31/2017 5,239,000 257,228 20.367145
8/15/2017 5,194,724 314,850 16.499044
7/31/2017 4,976,655 447,648 11.117340
7/14/2017 5,246,665 200,255 26.199920
6/30/2017 5,426,328 349,228 15.538067
6/15/2017 5,352,771 366,357 14.610806
5/31/2017 5,496,064 254,238 21.617791
5/15/2017 5,705,235 257,722 22.137167
4/28/2017 5,743,508 298,960 19.211627
4/13/2017 6,097,676 509,261 11.973577
3/31/2017 6,122,257 437,604 13.990405
3/15/2017 6,008,738 496,050 12.113170
2/28/2017 5,977,265 958,014 6.239225
2/15/2017 5,550,290 1,194,724 4.645667
1/31/2017 5,642,103 390,023 14.466078
1/13/2017 5,993,005 362,871 16.515525
12/30/2016 6,155,442 543,620 11.323060
12/15/2016 6,135,007 1,350,344 4.543292
11/30/2016 5,453,862 1,314,075 4.150343
11/15/2016 4,994,424 462,347 10.802328
10/31/2016 5,126,490 467,389 10.968358
10/14/2016 5,641,528 1,330,709 4.239490
9/30/2016 4,757,807 4,507,562 1.055517
9/15/2016 3,882,966 550,887 7.048571
8/31/2016 3,592,230 430,557 8.343216
8/15/2016 3,922,013 1,381,348 2.839265
7/29/2016 4,599,225 2,577,268 1.784535
7/15/2016 4,315,354 1,330,585 3.243201
6/30/2016 4,207,730 894,768 4.702593
6/15/2016 3,154,365 367,715 8.578288
5/31/2016 3,678,916 373,466 9.850739
5/13/2016 3,222,127 694,950 4.636488
4/29/2016 3,270,522 1,329,977 2.459082
4/15/2016 2,938,786 1,441,302 2.038980
3/31/2016 2,790,941 387,570 7.201128
3/15/2016 3,275,303 786,528 4.164255
2/29/2016 3,351,869 517,311 6.479408
2/12/2016 3,296,512 1,167,248 2.824174
1/29/2016 2,970,306 828,118 3.586815
1/15/2016 3,167,934 2,532,059 1.251130
12/31/2015 2,735,608 2,441,362 1.120525
12/15/2015 3,154,419 2,304,913 1.368563
11/30/2015 2,644,088 8,471,719 1.000000
11/13/2015 2,303,738 7,321,149 1.000000
10/30/2015 2,085,698 1,219,686 1.710029
Read more: http://www.nasdaq.com/symbol/avxl/short-interest#ixzz4Uw6pLhSi
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM

